Blackthorn Therapeuticsincis A Clinical Stage Neurobehavioral Health Company Based In San Franciscocaliforniafounded In 2015The Company Focuses On Developing Targeted Therapeutics For Brain Disordersparticularly Those Affecting The Central Nervous Systemcns Blackthorn Utilizes Its Proprietary Pathfinder Platforma Cloud Based Computational Psychiatry Tool That Integrates And Analyzes Multimodal Data To Enhance The Understanding Of Neurobehavioral Disorders One Of The Key Products In Blackthorn S Pipeline Is Btrx 140A Selective Kappa Opioid Receptor Antagonist Aimed At Treating Neuropsychiatric Disorderswhich Is Currently In Phase 2 Clinical Developmentthe Company Has Raised A Total Of $130 Million In Fundingwith Significant Backing From Investors Such As Google Ventures And Johnson & Johnson Innovationin 2020Blackthorn Was Acquired By Neumora Therapeuticsinc Continuing Its Influence In The Field Of Neurobehavioral Health Research
